NCT06118957View on ClinicalTrials.gov

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Thromboembolism
Interventions
DRUG

Enoxaparin

Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.

Trial Locations (1)

84132

University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery | Biotech Hunter | Biotech Hunter